Price History
Feb 9, 2026 — Apr 4, 2026Investment Snapshot
- P/B of 6.09 — trading above book value
- Piotroski F-Score 4/9 — moderate financial health
- Loss-making — negative ROE of -88.2%
- Revenue growing at 7,333% annually
Adagene Inc. (ADAG) is a Healthcare company operating in Pharmaceutical Preparations, listed on the NASDAQ , with a market capitalisation of $232 million . Key value metrics: P/B ratio 6.09, Piotroski F-Score 4 out of 9 (moderate financial health) .
Value Score
Key Metrics
Current vs 5-Year Average
Based on 5 years of SEC filingsRevenue & Net Income
Financial Statements
| Metric | FY22 | FY23 | FY24 |
|---|---|---|---|
| Revenue | $X.XB | $X.XB | $X.XB |
| Gross Profit | $X.XB | $X.XB | $X.XB |
| Operating Income | $X.XB | $X.XB | $X.XB |
| Net Income | $X.XB | $X.XB | $X.XB |
| EBITDA | $X.XB | $X.XB | $X.XB |
| Total Assets | $X.XB | $X.XB | $X.XB |
| Total Liabilities | $X.XB | $X.XB | $X.XB |
Adagene Inc. — Fundamental Analysis Summary
On financial health, ADAG shows a moderate Piotroski F-Score of 4/9, and negative return on equity of -88.2% (sector average: -19.8%), and minimal leverage with a debt-to-equity ratio of 0.19.
StockPik's composite Value Score for ADAG is 45/100 — reflecting current market or financial concerns. The score is built from ten fundamental signals: P/E, P/B, PEG ratio, P/S ratio, return on equity, gross margin, debt-to-equity, current ratio, dividend yield, and Piotroski F-Score.
ADAG shows revenue growing at 7,333% year-over-year, with earnings growing at 47%.